Compare Ginkgo Bioworks Holdings Inc (DNA) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Hasbro, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $8.9 (market cap $590.53M), while Hasbro, Inc. trades at $80.48 (market cap $11.10B). The key difference: Hasbro, Inc. is far larger — about 18.8× Ginkgo Bioworks Holdings Inc's market cap, and Hasbro, Inc. pays a 3.57% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | HAS | |
|---|---|---|
Market Cap | $590.53M | $11.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $105.88 |
52-Week Low | $5.48 | $70.95 |
Enterprise Value | $627.78M | $13.37B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Hasbro (HAS) trades at $79.53, showing modest daily gains but facing bearish technical signals. The company reported negative net income of -$322.4M in 2025 despite revenue growth to $4.7B, with profitability metrics showing strain. Recent earnings beats provide some optimism, while analyst consensus remains positive with a $104 price target representing 31% upside potential from current levels.
Investment outlook balances strong analyst support against fundamental challenges. The stock offers significant upside if management can improve profitability, but faces headwinds from negative margins and high debt levels. Key catalysts include Q2 2026 earnings on July 21 and execution of the company's 'aging up' strategy targeting adult consumers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
